8-K: vTv Therapeutics Provides Update on Cadisegliatin Program for Type 1 Diabetes

vTv Therapeutics announces the lifting of a clinical hold and the expected resumption of the Phase 3 CATT1 trial for Cadisegliatin in Q2 2025, aiming to improve glycemic control in Type 1 Diabetes patients.

Summary

• vTv Therapeutics is focused on developing oral drugs for chronic diseases, particularly Type 1 Diabetes (T1D).
• The company's lead drug candidate, Cadisegliatin (TTP399), is a liver-selective glucokinase activator in late-stage clinical development for T1D.
• The Phase 3 CATT1 trial is expected to resume in Q2 2025 after a clinical hold was lifted on March 14, 2025.
• A protocol amendment to reduce the trial duration from 12 to 6 months has been submitted, which is expected to expedite topline data without impacting key endpoints.
• Cadisegliatin aims to reduce hypoglycemia and improve glycemic control in T1D patients when used as an adjunct therapy to insulin.
• Approximately 80% of the 1.6 million Americans with T1D do not achieve target blood glucose control with current standard of care.
• The company is also exploring partnerships for additional upside and shareholder value.
• Cadisegliatin has potential expansion into Type 2 Diabetes (T2D) market.
• The company has a partnership with G42 Healthcare to investigate cadisegliatin as an adjunct therapy to insulin for people living with Type 2 diabetes.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the resumption of the Phase 3 trial and potential for partnerships, but acknowledges the risks and uncertainties associated with drug development.

Positives

• Clinical hold lifted on Cadisegliatin Phase 3 trial, allowing for resumption of the study.
• Protocol amendment to reduce trial duration will expedite topline data.
• Cadisegliatin has shown promise in reducing hypoglycemia and improving glycemic control in previous studies.
• Strong IP protection for Cadisegliatin provides market exclusivity through 2041.
• Partnerships with G42 Healthcare, Newsoara and Cantex provide potential revenue streams and development opportunities.
• Cadisegliatin targets a large unmet need in T1D, with potential expansion into T2D.

Negatives

• Cadisegliatin is still under investigation, and its safety and efficacy have not been fully established.
• There is no guarantee that Cadisegliatin will receive health authority approval or become commercially available.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Risks

• The development and regulatory approval process for Cadisegliatin is subject to risks and uncertainties.
• Clinical trial outcomes may not be favorable.
• The company's financial performance and fund-raising activities may differ materially from expectations.
• Competition from other companies developing treatments for diabetes.
• Reliance on partnerships for revenue and development.

Future Outlook

The company anticipates resuming the Phase 3 CATT1 trial in Q2 2025 and is focused on advancing the cadisegliatin program and exploring partnerships to enhance shareholder value.

Industry Context

The document highlights the need for improved glycemic control in T1D patients, as a significant portion of patients fail to achieve target blood glucose levels with current standard of care. Cadisegliatin aims to address this unmet need by providing an oral adjunct therapy to insulin, potentially reducing hypoglycemia and improving overall glycemic control.

Comparison to Industry Standards

• Cadisegliatin is positioned as a novel oral liver selective glucokinase activator, differentiating it from existing injectable GLP-1 receptor agonists like Ozempic (Novo Nordisk) and Trulicity (Eli Lilly) that are commonly used in Type 2 Diabetes.
• The company is targeting the T1D market, where there are limited oral adjunct therapies available, unlike the T2D market which has a wider range of oral medications such as metformin, sulfonylureas, and DPP-4 inhibitors.
• The CATT1 study is designed to assess the efficacy of cadisegliatin in patients utilizing continuous glucose monitoring (CGM), aligning with the increasing use of CGM technology in diabetes management.

Stakeholder Impact

• Positive impact on T1D patients by potentially improving glycemic control and reducing hypoglycemia.
• Potential benefits for shareholders through increased value and revenue streams.
• Opportunities for employees through continued development and expansion of the company.

Next Steps

• Resume the CATT1 Phase 3 trial in Q2 2025.
• Submit protocol amendment to reduce trial duration.
• Pursue partnerships for additional upside and shareholder value.
• Continue development of other pipeline candidates.

Key Dates

Keywords

Cadisegliatin, Type 1 Diabetes, T1D, Glucokinase Activator, Hypoglycemia, Glycemic Control, Clinical Trial, VTVT, Therapeutics, Insulin